Thread Research lands $50m infusion for decentralized trial tech
By Leo Adler on August 26, 2020
Thread Research, an organization providing numerous expertise and companies designed to allow decentralized scientific analysis, has acquired a capital dedication of as much as $50m from strategic healthcare traders, Water Street Healthcare Partners and JLL Partners. Outsourcing-Pharma (OSP) mentioned the funding with Thread president John Reites (JR), and the dramatic adjustments the decentralized trial discipline has seen in current months.
OSP: Please inform us about Thread Research, together with the historical past of the corporate, its key merchandise/capabilities, and what units you other than the competitors.
JR: Thread is a number one supplier of a proprietary, decentralized analysis platform and suite of supporting companies utilized by biopharma, CROs and life science organizations to remotely seize information from individuals and websites throughout, in-between and in lieu of in-clinic visits. We are serving to clients scale back examine timelines and budgets with digital visits and convey research from the clinic to sufferers’ houses.
Thread supplies key platform options comparable to eConsent, eCOA/ePRO, sensors, reminders and telehealth Virtual Visits to assist distant information seize, hybrid digital research and totally decentralized research in key therapeutic areas.
Since supporting our first decentralized examine in 2015, we have now continued to reinforce our platform and companies, and we have now supported greater than 100 research with availability in over 40 international locations. Our experience ensuing from the sheer quantity and international footprint of our research and the credibility we’ve established within the business is what actually units us aside.
Leo Adler is scientist, writer and poet. His mother is an Artist and father is preschool teacher. He attain a bachelor's degree in English. He has 3 years experience in online news writing. Now he is works as a news writer on Guru Online News.